A meta-analysis of randomized trials found that weight management strategies — including GLP-1 agonists and bariatric surgery — significantly increase the risk of gallbladder and biliary disease, with risk proportional to the amount of weight lost.
36% increased riskWeight management strategies raised gallbladder/biliary disease risk by 36% compared to placebo or controls
What the researchers found
Weight management strategies were associated with a 36% increased risk of gallbladder/biliary disease (OR 1.361, 95% CI 1.147-1.614), including increased risks of gallstones, cholecystitis, and cholecystectomy. GLP-1 receptor agonists specifically showed elevated risk.
Why it matters
As potent GLP-1 drugs produce larger weight losses in more patients, gallbladder complications may become a growing clinical concern. This meta-analysis quantifies the risk and highlights the need for monitoring, especially with higher-dose treatments.
The numbers in context
RCTs with ≥12-week duration included. Significant increase in gallbladder/biliary events with weight loss. Risk proportional to weight reduction magnitude.
How the study worked
Systematic review and meta-analysis of randomized controlled trials with at least 12 weeks duration comparing anti-obesity medications to placebo or bariatric surgery to less intensive weight management strategies.
Who was studied
Patients in weight loss intervention RCTs (drugs and surgery)
What this study cannot tell us
Some included trials had short follow-up. Individual risk factors for gallbladder disease (age, sex, baseline BMI) were not fully disaggregated. Different weight loss mechanisms may carry different risk profiles. Could not determine optimal monitoring strategies.
How to read the evidence
Strong evidence — systematic review and meta-analysis of multiple randomized controlled trials with low heterogeneity (I² = 3.5%).
When this study was published
Published in 2024, synthesizing trials across the modern era of anti-obesity medications including GLP-1 agonists.
The bigger picture
Rapid weight loss has long been known to increase gallstone risk. As GLP-1 agonists like semaglutide and tirzepatide become the dominant weight loss approach, this meta-analysis provides critical safety data that should inform monitoring guidelines and patient counseling about gallbladder symptoms during treatment.
Questions still open
- Should patients starting GLP-1 agonists for weight loss receive prophylactic ursodeoxycholic acid to prevent gallstones?
- Is the gallbladder risk driven by the rate of weight loss or the total amount lost?
- Do newer dual/triple agonists (tirzepatide, retatrutide) carry even higher gallbladder risk given their greater weight loss efficacy?
Common questions
Should I worry about gallbladder problems if I'm taking semaglutide or a similar drug?
Does losing weight faster make gallbladder problems more likely?
Read the original research
Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta-analysis of randomized clinical trials.
Obesity reviews : an official journal of the International Association for the Study of Obesity, 25(6), e13725
Citation
Yang, Wenjia; Wu, Han; Cai, Xiaoling; Lin, Chu; Luo, Yingying; Hu, Suiyuan; Li, Zonglin; Jiao, Ruoyang; Bai, Shuzhen; Liu, Geling; Yang, Xiaolin; Ji, Linong. (2024). Weight reduction and the risk of gallbladder and biliary disease: A systematic review and meta-analysis of randomized clinical trials.. Obesity reviews : an official journal of the International Association for the Study of Obesity, 25(6), e13725. https://doi.org/10.1111/obr.13725